This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

Pediatric neurologist / epileptologist KOL on SYNGAP1 and neurodevelopmental disorders

Ticker(s): CAMP4 THERAPEUTICS, BIIB, IONS

Who's the expert?

US‑based pediatric neurologist / epileptologist at a top‑tier academic children’s hospital with: ≥5–10 years experience in developmental epileptic encephalopathies and neurogenetics Active clinical and research focus on SYNGAP1‑related disorders and related monogenic epilepsies Experience as PI or sub‑I on interventional trials in rare pediatric CNS disorders (including ASO or gene‑targeted therapies if possible).

Interview Goal
Obtain expert clinical and translational insights from a leading pediatric neurologist / epileptologist at a major US academic center (e.g., Johns Hopkins) with deep expertise in SYNGAP1‑related disorders, developmental epileptic encephalopathies, and neurogenetics. Discuss current standards of care, diagnostic pathways, natural history, meaningful endpoints and outcome measures, caregiver perspectives, and views on emerging antisense/RNA‑based upregulation strategies for SYNGAP1.

Are You Interested In These Questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.